<p>Kazmira Pharmacy 是全国首家获得许可的 503A 配方药房，提供无 THC 的处方 CBD。</p>
<p>, /PRNewswire/ -- Kazmira Therapeutics 今天宣布正式推出首个仅限处方的类 cannabinoids (CBD) 药房 Kazmira Pharmacy。这家获得许可并通过 LegitScript 认证的 503A 配方药房专注于纯配方的 cannabidiol，且不含任何四氢大麻酚 (THC) 的痕迹，THC 是大麻中的致醉成分。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Kazmira Therapeutics 总部位于科罗拉多州沃特金斯。</p>
<p>联合创始人兼首席执行官 Priyanka Sharma 博士表示：“我们的目标是将 CBD 从非处方产品转变为基于证据的药房配药药物。” Sharma 指出：“现在，提供者可以与患者合作，开具最适合他们独特健康问题的个性化治疗方案。”</p>
<p>Sharma 解释了超纯 CBD 对多种健康状况的影响，包括疼痛管理、焦虑障碍和物质滥用障碍的研究。仅限处方的 CBD 可能会对那些对市场上其他治疗反应不佳的患者产生积极影响。</p>
<p>考虑到大麻和大麻法律在全国辩论中处于中心地位，Kazmira 药房的时机非常理想。2025 年 12 月，特朗普总统签署了一项行政命令，将大麻重新分类为 III 类药物，实际上禁止市场上含有超过 0.4 毫克 THC 的非处方产品。</p>
<p>“Kazmira 不是另一家对监管变化做出反应的 CBD 公司。我们有一个有意的、以基础设施为先的医疗保健启动，展示了如何将 CBD 整合到临床护理中，而不依赖于健康漏洞、零售分销或未经批准的药物声明，” Sharma 解释道。“随着审查的增加和传统大麻模式面临压力，医疗保健利益相关者需要明确哪些能够在过渡中存活。此次推出提供了一个可信的蓝图，展示了当 CBD 被视为药物而非松散监管的非处方产品时的未来。”</p>
<p>Kazmira Therapeutics 的医疗顾问 Gautham Oroskar 医生相信，这一模式将改善 CBD 作为医疗治疗的临床采用。</p>
<p>“当你将醉酒、损伤和药物检测问题排除在外时，医生可以像评估任何其他治疗化合物一样评估患者对 CBD 的反应，” 他说。“它成为他们工具箱中的一种治疗工具，具有明确的作用机制，而不是缺乏临床监督的补充品。”</p>
<p>Kazmira Pharmacy 是 LegitScript 医疗保健认证的，这是一项广泛认可的医疗合规、透明度和患者安全标准。该认证验证了 Kazmira 对药房合规、患者安全和 CBD 配方的监管标准的承诺。获得 LegitScript 认证后，Kazmira 有望解锁需要经过验证的医疗合规的高价值战略合作伙伴关系，从而实现可持续的规模增长。</p>
<p>虽然最初仅在科罗拉多州推出，但该药房的结构旨在扩展到其他州。Kazmira 正在与全国各州的药房委员会合作进行许可，目标是在 2026 年再增加 20 个或更多州，包括亚利桑那州、佛罗里达州、德克萨斯州和犹他州。</p>
<p><strong>关于 Kazmira Pharmacy</strong></p>
<p>Kazmira Pharmacy 运营着首个仅限处方的类 cannabinoids (CBD) 治疗平台，旨在为医疗保健系统服务，而非健康产品通道。根据获得许可的 503A 药房标准运营，Kazmira 被授权将无 THC 的 CBD 分离物作为活性药物成分 (API) 进行配方。</p>
<p><strong>媒体联系人：</strong> Josh Birch</p>
<p>媒体关系经理</p>
<p>KNB Communications</p>
<p>[email protected]</p>
<p>来源 Kazmira Pharmacy</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIwJk5ld3NJdGVtSWQ9Tlk2Njg1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjAxMDI3UFJfTkVXU19VU1BSX19fX19OWTY2ODU5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIwJk5ld3NJdGVtSWQ9Tlk2Njg1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjAxMDI3UFJfTkVXU19VU1BSX19fX19OWTY2ODU5"/></p>

<p>Kazmira Therapeutics 推出了 Kazmira Pharmacy，这是美国首家获得许可的 503A 配药药房，提供仅限处方的无 THC CBD。联合创始人 Priyanka Sharma 旨在将 CBD 从非处方药转变为基于证据的医学，允许针对各种健康问题进行个性化治疗。该药房获得了 LegitScript 认证，确保合规性和安全性，并计划在 2026 年前扩展到其他州。此举旨在将 CBD 整合到临床护理中，为其作为治疗工具的使用提供一个可信的模型</p>

<p><em>Kazmira Pharmacy is the first licensed 503A compounding pharmacy in the country offering THC-free, prescription-only CBD.</em></p>
<div class="lb-trans"><p>Kazmira Pharmacy 是全国首家获得许可的 503A 配方药房，提供无 THC 的处方 CBD。</p>
</div><p>, /PRNewswire/ -- Kazmira Therapeutics announced today the official launch of a first-of-its-kind, prescription-only cannabinoid (CBD) pharmacy, Kazmira Pharmacy. This licensed and LegitScript certified 503A compounding pharmacy specializes in pure compounded cannabidiol without any trace of tetrahydrocannabinol (THC), the intoxicating component in hemp.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Kazmira Therapeutics 今天宣布正式推出首个仅限处方的类 cannabinoids (CBD) 药房 Kazmira Pharmacy。这家获得许可并通过 LegitScript 认证的 503A 配方药房专注于纯配方的 cannabidiol，且不含任何四氢大麻酚 (THC) 的痕迹，THC 是大麻中的致醉成分。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Kazmira Therapeutics headquarters in Watkins, Colorado.</p>
<div class="lb-trans"><p>Kazmira Therapeutics 总部位于科罗拉多州沃特金斯。</p>
</div><p>Co-founder and Co-CEO Priyanka Sharma, Ph.D., said, &#34;The goal is to move CBD from an over-the-counter product to evidence-based, pharmacy-dispensed medicine,&#34; Sharma noted. &#34;Now, providers can work with their patients to prescribe personalized treatment that is best for their unique health concerns.&#34;</p>
<div class="lb-trans"><p>联合创始人兼首席执行官 Priyanka Sharma 博士表示：“我们的目标是将 CBD 从非处方产品转变为基于证据的药房配药药物。” Sharma 指出：“现在，提供者可以与患者合作，开具最适合他们独特健康问题的个性化治疗方案。”</p>
</div><p>Sharma explained the impact of ultra pure CBD has been studied on a variety of health conditions, including pain management, anxiety disorders, and substance abuse disorders. Prescription-only CBD could make a difference for patients who may not have responded well to other treatments on the market.</p>
<div class="lb-trans"><p>Sharma 解释了超纯 CBD 对多种健康状况的影响，包括疼痛管理、焦虑障碍和物质滥用障碍的研究。仅限处方的 CBD 可能会对那些对市场上其他治疗反应不佳的患者产生积极影响。</p>
</div><p>The timing for Kazmira's pharmacy is ideal given hemp and marijuana laws have been front and center in national debates. In December 2025, President Trump signed an Executive Order that will reschedule cannabis to Schedule III drug, effectively banning over-the-counter products currently on the market that contain more than 0.4 milligrams of THC.</p>
<div class="lb-trans"><p>考虑到大麻和大麻法律在全国辩论中处于中心地位，Kazmira 药房的时机非常理想。2025 年 12 月，特朗普总统签署了一项行政命令，将大麻重新分类为 III 类药物，实际上禁止市场上含有超过 0.4 毫克 THC 的非处方产品。</p>
</div><p>&#34;Kazmira is not another CBD company reacting to regulatory change. We have an intentional, infrastructure-first healthcare launch that demonstrates how CBD can be integrated into clinical care without relying on wellness loopholes, retail distribution, or unapproved drug claims,&#34; Sharma explained. &#34;As scrutiny increases and legacy hemp models face pressure, healthcare stakeholders need clarity on what survives the transition. This launch offers a credible blueprint for what the future of CBD looks like when treated as medicine, not loosely-regulated over-the-counter products.&#34;</p>
<div class="lb-trans"><p>“Kazmira 不是另一家对监管变化做出反应的 CBD 公司。我们有一个有意的、以基础设施为先的医疗保健启动，展示了如何将 CBD 整合到临床护理中，而不依赖于健康漏洞、零售分销或未经批准的药物声明，” Sharma 解释道。“随着审查的增加和传统大麻模式面临压力，医疗保健利益相关者需要明确哪些能够在过渡中存活。此次推出提供了一个可信的蓝图，展示了当 CBD 被视为药物而非松散监管的非处方产品时的未来。”</p>
</div><p>Gautham Oroskar, MD, a medical advisor at Kazmira Therapeutics, believes the model will improve clinical adoption of CBD as a medical treatment.</p>
<div class="lb-trans"><p>Kazmira Therapeutics 的医疗顾问 Gautham Oroskar 医生相信，这一模式将改善 CBD 作为医疗治疗的临床采用。</p>
</div><p>&#34;When you take intoxication, impairment, and drug-testing concerns off the table, physicians can evaluate how their patients respond to CBD the same way they evaluate any other therapeutic compound,&#34; he said. &#34;It becomes a therapeutic tool in their toolkit with a defined mechanism of action, not a supplement with weak clinician oversight.&#34;</p>
<div class="lb-trans"><p>“当你将醉酒、损伤和药物检测问题排除在外时，医生可以像评估任何其他治疗化合物一样评估患者对 CBD 的反应，” 他说。“它成为他们工具箱中的一种治疗工具，具有明确的作用机制，而不是缺乏临床监督的补充品。”</p>
</div><p>Kazmira Pharmacy is LegitScript Healthcare certified, a widely recognized standard for healthcare compliance, transparency, and patient safety. The certification validates Kazmira's commitment to pharmacy compliance, patient safety, and regulatory standards in CBD compounding. With LegitScript certification secured, Kazmira is positioned to unlock high-value strategic partnerships that require verified healthcare compliance, enabling sustainable growth at scale.</p>
<div class="lb-trans"><p>Kazmira Pharmacy 是 LegitScript 医疗保健认证的，这是一项广泛认可的医疗合规、透明度和患者安全标准。该认证验证了 Kazmira 对药房合规、患者安全和 CBD 配方的监管标准的承诺。获得 LegitScript 认证后，Kazmira 有望解锁需要经过验证的医疗合规的高价值战略合作伙伴关系，从而实现可持续的规模增长。</p>
</div><p>While initially launching only in Colorado, the pharmacy is structured to expand into additional states. Kazmira is working with State Pharmacy Boards across the country in licensure, targeting an additional 20 or more states —including Arizona, Florida, Texas, and Utah — in 2026.</p>
<div class="lb-trans"><p>虽然最初仅在科罗拉多州推出，但该药房的结构旨在扩展到其他州。Kazmira 正在与全国各州的药房委员会合作进行许可，目标是在 2026 年再增加 20 个或更多州，包括亚利桑那州、佛罗里达州、德克萨斯州和犹他州。</p>
</div><p><strong>About Kazmira Pharmacy</strong></p>
<div class="lb-trans"><p><strong>关于 Kazmira Pharmacy</strong></p>
</div><p>Kazmira Pharmacy operates a first-of-its-kind prescription cannabinoid (CBD) therapy platform, built for the healthcare system — not the wellness aisle. Operating under licensed 503A pharmacy standards, Kazmira is authorized to compound THC-free CBD isolate as an active pharmaceutical ingredient (API).</p>
<div class="lb-trans"><p>Kazmira Pharmacy 运营着首个仅限处方的类 cannabinoids (CBD) 治疗平台，旨在为医疗保健系统服务，而非健康产品通道。根据获得许可的 503A 药房标准运营，Kazmira 被授权将无 THC 的 CBD 分离物作为活性药物成分 (API) 进行配方。</p>
</div><p><strong>Media Contact:</strong> Josh Birch</p>
<div class="lb-trans"><p><strong>媒体联系人：</strong> Josh Birch</p>
</div><p>Media Relations Manager</p>
<div class="lb-trans"><p>媒体关系经理</p>
</div><p>KNB Communications</p>
<div class="lb-trans"><p>KNB Communications</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Kazmira Pharmacy</p>
<div class="lb-trans"><p>来源 Kazmira Pharmacy</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIwJk5ld3NJdGVtSWQ9Tlk2Njg1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjAxMDI3UFJfTkVXU19VU1BSX19fX19OWTY2ODU5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY66859&amp;Transmission_Id=202601201027PR_NEWS_USPR_____NY66859&amp;DateId=20260120"/></p>

首个此类医疗级大麻药房在科罗拉多州开业